Skip to main content

How long do Repatha side effects last?

Medically reviewed by Melisa Puckey, BPharm. Last updated on Sep 19, 2023.

Official answer

by drugclasses.com

Clinical trials for Repatha do not detail how long the side effects of Repatha last, therefore it is hard to find accurate information about this.

Often side effects last the length of time the medication stays in the body and side effects decrease as the amount of medication decreases in your body.

How long a medication stays in the body depends on its half-life. Repatha’s half-life ranges between 11 and 17 days, depending on personal variation.

So once you have had your last dose then in 11 to 17 days half of the medications will have been removed from your body, and then after another 11 to 17 days there will only be 25% medication left in your body, and so on.

For a lot of medications the time for most of the medication to be removed from your body is 5.5 half-lives. For Repatha this would range from:

  • 11 days X 5.5 = 60.5 days
  • 17 days X 5.5 = 93.5 day

Therefore most of the medication will be removed from your body between 60.5 days and 93.5 days (approximately 2 to 3 months) which is when you would hope to be side effect free.

References

Read next

Are there any dangers of taking Repatha?

A serious danger of taking Repatha (evolocumab) includes a possibly life-threatening allergic reaction. Also tell your doctor if you are allergic to rubber or latex. Other side effects, which could be serious in some people, include high blood sugar levels (diabetes), respiratory tract infections, urinary tract infections (UTI), high blood pressure, and influenza (flu). Continue reading

Praluent vs Repatha: What's the difference?

The differences between Repatha (evolocumab) and Praluent (alirocumab) are their active ingredients, number of treatment indications, dosage forms available and number of strengths available in syringe and pens forms. Continue reading

What is the difference between Leqvio and Repatha?

Leqvio and Repatha are both injectable medicines that are used for the treatment of high cholesterol, by specifically lowering low density lipoprotein (LDL) levels. Although they both inhibit PCSK9 they work by different mechanisms. Repatha is a monoclonal antibody that binds directly to PCSK9 in the liver preventing it from binding to LDL receptors. Leqvio blocks the PCSK9 protein by interfering with the translation of PCSK9 messenger RNA. Both have the same result – and that is freeing up LDL receptors on the surface of liver cells which allows LDL cholesterol to be removed from the blood. Continue reading

Related medical questions

Drug information

Related support groups